Filing Flows › Ultragenyx Pharmaceutical (RARE) › Q3 2026
Ultragenyx Pharmaceutical (RARE) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Ultragenyx Pharmaceutical (RARE) reported revenue of $173M for the third quarter 2026 (Q3 2026), +8% from a year earlier and -19% from the quarter before. Operating margin was -63.6%, net loss $118M (68.2% of revenue).
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $173M | -19% | +8% |
| Operating profit | −$110M | — | — |
| Net earnings | −$118M | — | — |
| Operating cash flow | −$43.0M | — | — |
What changed
Revenue was $173.0M in Q3 2026, up 8% year over year and down 19% from the previous quarter. Product was the largest line at 61% of revenue. Product added $10.0M year over year (up 11%), 77% of the total change.
Operating costs exceeded revenue by $110.0M, an operating margin of -63.6%. Total costs fell 15% while revenue rose 8%. The fastest-growing cost line was Other operating costs (+14%). The quarter ended with a net loss of $118.0M, wider than the previous quarter's $92.0M loss.
Operating cash flow was −$43.0M. Non-cash charges added back $9.0M of depreciation and amortization and $34.0M of share-based compensation. Working capital and other items added $32.0M. Capital expenditures of $2.0M exceeded it, leaving free cash flow of −$45.0M.
Questions
What was Ultragenyx Pharmaceutical's revenue in the third quarter 2026?
Ultragenyx Pharmaceutical (RARE) reported revenue of $173M for the third quarter 2026 (Q3 2026), +8% from a year earlier and -19% from the quarter before.
Was Ultragenyx Pharmaceutical profitable in the third quarter 2026?
Operating loss was $110M (-63.6% of revenue) and net loss $118M.